Inamed is an international Contract Research Organization (CRO) providing its clients with the full range of services, required for the planning, conduct and evaluation of clinical trials throughout all phases, for nearly two decades. Founded in 1998, Inamed is located in the periphery of Munich. Complementing our solid experience in conducting clinical trials in various indications, Inamed's team of inhalation and clinical experts provides our sponsors with a unique spectrum of services. Besides our clinical trial operations and state-of the-art, in-house clinical pharmacology unit with 12 beds (+6 intensive monitoring beds), Inamed performs in-vitro studies in its own labs and is a leading CRO in continental Europe able and approved to perform scintigraphy studies, with radiolabeled compounds, under GMP requirements. Our studies deliver the highest quality data and can enhance your clinical trials and development projects for drugs and inhalation devices. Inamed offers an opportunity for sponsors to get their products to market more successfully.
Ranging from dedicated respiratory clinical trials, such as Phase I-IV with inhaled compounds or inhalation devices, up to specialized clinical trials such as Flow-Profile or scintigraphy lung deposition studies, Inamed provides the full range of services.Read more
At its own in-house Clinical Pharmacology Unit, Inamed is prepared to conduct all kinds of early phase clinical trials, ranging from First-in-Man studies up to studies with complex endpoints.Read more
Reflecting our consistent commitment to advancing scientific improvements for clinical trial designs, Inamed’s CEO / CMO Dr. Wolfgang Timmer, is giving a lecture on Clinical First in Man Studies (FIM), Determination of the Bioavailability and Important Interaction Studies at the German Tox Summit. Read more
After eight, successful, years as CEO Dr. Matthias Heil went into his, well deserved, retirement, passing the company to the capable hands of Dr. Wolfgang Timmer, former CMO and Managing Director of Inamed. Read more